

KSR Ite

A practical approach to diagnostic appraisals

Marie Westwood


Kleijnen Systematic Reviews Ltd, York, U.K. www.systematic-reviews.com marie@systematic-reviews.com



A diagnostic appraisal pathway



KSR Ltd





What is the aim of a diagnostic appraisal?





Does the test have a potential role in the NHS?

What does the test add to what is already being provided?

Accuracy versus clinical benefit

Does the test result in benefits perceived by the patient?

Clinical benefit

- Improved health outcomes
- Changes to management
- Reassurance?



KSR Ltd

Topic selected – SonoVue ✓



Potential position in the care pathway





Replacement of an existing test

- Improved discriminatory value
- Better patient experience/fewer adverse effects
- Quicker
- Cheaper

Addition to an existing test

- Improved discriminatory value
- Improved coverage

Triage

 Sensitive test which could be used to rapidly rule-out further investigation with more invasive/expensive tests



Scoping and question setting





Contrast enhanced ultrasound of the liver using SonoVue® (sulphur hexafluoride microbubbles)

- Target group adults who require liver imaging by ultrasound techniques
- Other indications echocardiography, Doppler of the macrovasculature,
 Doppler of the microvasculature (including breast and liver lesions)
- Existing treatments and comparators:
 US, CT and MRI (all with and without contrast), biopsy and first generation mircobubble contrast agents.



KSR Lto

Final scope published ✓



Research question





To compare the clinical and cost-effectiveness of contrast enhanced ultrasound (CEUS) using the contrast agent SonoVue® with contrast-enhanced CT and contrast-enhanced MRI for the assessment of adults with focal liver lesions (FLL), in whom previous liver imaging has been inconclusive.

- Cirrhosis surveillance
- Detection of liver metastases from colorectal cancer
- Incidentally detected focal liver lesions



KSR Lto

Final protocol published



Direct vs. 'linked-evidence' approach





 Trial data to address the question: do patients who undergo the diagnostic test have better health outcomes than those who do not?

 Accuracy + prognostic link between the target condition and morbidity/mortality + effective intervention

SonoVue® – three clinical applications = three cost-effectiveness models

Comparators – other contrast-enhanced imaging modalities



Modelling approach





published model for cirrhosis surveillance

new cirrhosis model modified compare confirmatory imaging methods and allow uncertainty published model for liver metastases detection

new metastases model modified compare imaging methods after inconclusive ultrasound

new incidental focal liver lesions model
Combination and modification
change to point of diagnosis (hepatocellular carcinoma)
change to handling of false positives and false negatives



Conclusion of the SonoVue® assessment



KSR Ltd

Systematic review

 SonoVue® could provide similar diagnostic performance to other imaging modalities (CECT and CEMRI) for the three main clinical applications considered

Cost-effectiveness analyses

SonoVue® instead of CEMRI was cost-effective. SonoVue® instead of CECT was considered cost-effective in the surveillance of cirrhosis and characterisation of incidentally detected focal liver lesions, with similar costs and effects for the detection of CRC liver metastases



KSR Lto

Report submitted✓



NICE guidance DG5



KSR Ltd

"SonoVue® is recommended for use with ultrasound for examining abnormal-looking areas in the liver that are noticed, but cannot be properly identified, using normal ultrasound. These areas may have been noticed during routine scanning. If they were noticed when looking for cancer that has spread from another part of the body, SonoVue® is recommended if the person cannot have or does not want a CT (computed tomography) scan. If they were noticed in someone with cirrhosis who is having their liver checked, SonoVue® is recommended if the person cannot have or does not want an MRI (magnetic resonance imaging) scan."



The future – companion diagnostics



KSR Ltd

- Trial data are generally available for test and treatment
- Different trials may use different tests, but trials do not usually compare tests
- No reference standard test tests may select different populations

Possible approaches

- Compare accuracy of test(s) to predict response to treatment
- Compare treatment effects obtained when participants are selected using different tests

Problem

Other variables may effect these measures



References



KSR Ltd

Van Ravesteijn H, van Dijk I, Darmon D, et al. The reassuring value of diagnostic tests: a systematic review. Patient Education and Counseling. 2012;86:3-8.

Rolfe A and Burton C. Reassurance after diagnostic testing with a low pretest probability of serious disease: Systematic review and meta-analysis. JAMA Internal Medicine. 2013;173(6):407-16.

Takwoingi DVM, Leeflang MMG and Deeks JJ. Empirical evidence of the importance of comparative studies of diagnostic test accuracy. Annals of Internal medicine. 2013;158:544-54.

Lijmer JG and Bossuyt PMM. Diagnostic testing and prognosis: the randomized controlled trial in test evaluation research. in The Evidence Base of Clinical Diagnosis: Theory and Methods of Diagnostic research. Editors: Knottnerus JA and Buntinx F. 2009 Blackwell Publishing.